Amgen clotting drug gets FDA nod

Now it's time for the press release: The FDA approved Amgen's Nplate drug to treat a rare blood-clotting disorder that causes the body to attack its own platelets. Last month, Amgen mistakenly announced that Nplate had won the FDA nod, and had to retract the press release. This time, though, it's for real. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.